8-K Announcements
6Material company update
Mar 20, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Mar 3, 2026·SEC
7.125% Fixed-Rate Reset Subordinated Debentures due 2052(RZC)Earnings, Financials & Key Ratios
RZC•NYSE•Insurance & Managed Care
$25.39
$1.7B mkt cap·2.4× P/E·Price updated May 6, 2026
AboutReinsurance Group of America, Inc. is a holding company, which engages in the provision of traditional and non-traditional life and health reinsurance products. It operates through the following segments: U.S. and Latin America, Canada, Europe, Middle East, and Africa, Asia Pacific, and Corporate and Other. The U.S. and Latin America segment markets individual and group life and health reinsurance to domestic clients for a variety of products through yearly renewable term agreements, coinsurance, and modified coinsurance. The Canada segment offers individual life reinsurance, and, to a lesser extent, creditor, group life and health, critical illness, and disability reinsurance, through yearly renewable term and coinsurance agreements. The Europe, Middle East, and Africa segment serves individual and group life and health products through yearly renewable term and coinsurance agreements, reinsurance of critical illness coverage that provides a benefit in the event of the diagnosis of a pre-defined critical illness, and underwritten annuities. The Asia Pacific segment consists of individual and group life and health reinsurance, critical illness coverage, disability, and superannuation through yearly renewable term and coinsurance agreements. The Corporate and Other segment consists of investment income from unallocated invested assets, investment related gains, and losses and service fees. The company was founded in 1973 and is headquartered in Chesterfield, MO.Show more
- Revenue$22.04B+19.9%
- Combined Ratio95.55%+2.0%
- Net Income$717M-20.5%
- Return on Equity7.14%-35.3%
- Medical Cost Ratio88.71%+1.6%
- Operating Margin4.45%-29.5%
- Net Margin3.25%-33.7%
- ROA0.66%-32.9%
- Equity / Assets9.19%-2.2%
- Book Value per Share163.02+19.3%
- Tangible BV/Share161.03+19.8%
- Debt/Equity0.46-4.2%
RZC Key Insights
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓17 consecutive years of dividend growth
- ✓Trading near 52-week high
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗High loss ratio of 88.7%
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RZC Price & Volume
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) stock price & volume — 10-year historical chart
Loading chart...
RZC Growth Metrics
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.29%
5 Years9.19%
3 Years11.13%
TTM2.28%
Profit CAGR
10 Years0.47%
5 Years-3.79%
3 Years-15.06%
TTM19.26%
EPS CAGR
10 Years0.93%
5 Years-4.66%
3 Years5.88%
TTM-80.17%
Return on Capital
10 Years1.39%
5 Years1.05%
3 Years1%
Last Year0.91%
RZC Recent Earnings
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) EPS & revenue vs analyst estimates — last 4 quarters
Q1 2026Latest
Feb 5, 2026EPS
$7.75
Revenue
$6.6B
Q1 2024
Feb 1, 2024EPS
$4.73
Revenue
$5.0B
Q4 2023
Nov 2, 2023EPS
$5.57
Revenue
—
Q3 2023
Aug 4, 2023EPS
$4.40
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 5, 2026 | $7.75 | $6.6B |
| Q1 2024 | Feb 1, 2024 | $4.73 | $5.0B |
| Q4 2023 | Nov 2, 2023 | $5.57 | — |
| Q3 2023 | Aug 4, 2023 | $4.40 | — |
Based on last 7 quarters of dataView full earnings history →
RZC Peer Comparison
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) competitors in Reinsurance (P&C and life) — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GS | 291.19B | 937.35 | 23.12 | 17% | 12.59% | 5.06 | ||
 MS | 307.53B | 193.28 | 24.31 | 16.83% | 14.57% | 3.42 | ||
 JEF | 10.68B | 51.75 | 18.29 | 2.93% | 7.7% | 0.17 | ||
 LAZ | 4.37B | 46.56 | 21.46 | 3.25% | 26.7% | 2.61 | ||
 HLI | 10.27B | 147.23 | 25.30 | 24.81% | 20.14% | 0.20 | ||
 MC | 4.68B | 63.79 | 21.70 | 26.98% | 37.88% | 0.39 | ||
 PJT | 3.68B | 152.14 | 22.78 | 14.77% | 20.08% | 0.41 | ||
 OXSQ | 165.4M | 1.89 | -7.56 | 32.01% | -24.71% | 1.08 |
Compare RZC vs Peers
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RZC Income Statement
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.52B | 12.52B | 12.88B | 14.2B | 14.58B | 16.06B | 15.88B | 18.39B | 22.04B | 22.27B |
| Revenue Growth % | 10.59% | 8.63% | 2.88% | 10.27% | 2.71% | 10.13% | -1.13% | 15.82% | 19.85% | 2.28% |
| Medical Costs & Claims | 9.67B | 10.49B | 11.07B | 12.1B | 13.04B | 14.21B | 14.31B | 16.06B | 19.55B | 19.36B |
| Medical Cost Ratio % | 83.92% | 83.8% | 85.95% | 85.2% | 89.41% | 88.46% | 90.11% | 87.33% | 88.71% | 86.92% |
| Gross Profit | 1.85B▲ 0% | 2.03B▲ 9.4% | 1.81B▼ 10.8% | 2.1B▲ 16.1% | 1.54B▼ 26.5% | 1.85B▲ 20.1% | 1.57B▼ 15.3% | 2.33B▲ 48.4% | 2.49B▲ 6.7% | 2.91B▲ 0% |
| Gross Margin % | 16.08% | 16.2% | 14.05% | 14.8% | 10.59% | 11.54% | 9.89% | 12.67% | 11.29% | 13.08% |
| Gross Profit Growth % | 26.53% | 9.45% | -10.8% | 16.14% | -26.51% | 20.08% | -15.26% | 48.38% | 6.74% | - |
| Operating Expenses | 808.96M | 885M | 963M | 969M | 991M | 469M | 853M | 1.17B | 1.51B | 1.66B |
| OpEx / Revenue % | 7.02% | 7.07% | 7.48% | 6.82% | 6.8% | 2.92% | 5.37% | 6.37% | 6.84% | 7.44% |
| Depreciation & Amortization | 26.85M | 53M | 45M | 49M | 49M | 43M | 38M | 41M | 46M | 0 |
| Combined Ratio % | 90.94% | 90.87% | 93.43% | 92.03% | 96.21% | 91.38% | 95.48% | 93.69% | 95.55% | 94.36% |
| Operating Income | 1.04B▲ 0% | 1.14B▲ 9.5% | 846M▼ 26.0% | 1.13B▲ 33.8% | 553M▼ 51.1% | 1.39B▲ 150.5% | 718M▼ 48.2% | 1.16B▲ 61.6% | 980M▼ 15.5% | 1.25B▲ 0% |
| Operating Margin % | 9.06% | 9.13% | 6.57% | 7.97% | 3.79% | 8.62% | 4.52% | 6.31% | 4.45% | 5.64% |
| Operating Income Growth % | 40.17% | 9.49% | -25.98% | 33.81% | -51.15% | 150.45% | -48.16% | 61.56% | -15.52% | - |
| EBITDA | 1.07B | 1.2B | 891M | 1.18B | 602M | 1.43B | 756M | 1.2B | 1.03B | 1.61B |
| EBITDA Margin % | 9.29% | 9.56% | 6.92% | 8.32% | 4.13% | 8.89% | 4.76% | 6.53% | 4.65% | 7.22% |
| Interest Expense | 137.62M | 146M | 147M | 173M | 170M | 139M | 191M | 257M | 304M | 354M |
| Non-Operating Income | -137.62M | -146M | -147M | -173M | -170M | -139M | -191M | -257M | -304M | -354M |
| Pretax Income | 1.04B▲ 0% | 1.14B▲ 9.5% | 846M▼ 26.0% | 1.13B▲ 33.8% | 553M▼ 51.1% | 1.39B▲ 150.5% | 718M▼ 48.2% | 1.16B▲ 61.6% | 980M▼ 15.5% | 1.25B▲ 0% |
| Pretax Margin % | 9.06% | 9.13% | 6.57% | 7.97% | 3.79% | 8.62% | 4.52% | 6.31% | 4.45% | 5.64% |
| Income Tax | 342.5M | -679M | 130M | 262M | 138M | 215M | 197M | 251M | 256M | 381M |
| Effective Tax Rate % | 32.81% | -59.41% | 15.37% | 23.14% | 24.95% | 15.52% | 27.44% | 21.64% | 26.12% | 30.36% |
| Net Income | 701.44M▲ 0% | 1.82B▲ 159.8% | 716M▼ 60.7% | 870M▲ 21.5% | 415M▼ 52.3% | 1.17B▲ 181.9% | 517M▼ 55.8% | 902M▲ 74.5% | 717M▼ 20.5% | 867M▲ 0% |
| Net Margin % | 6.09% | 14.56% | 5.56% | 6.13% | 2.85% | 7.28% | 3.26% | 4.9% | 3.25% | 3.89% |
| Net Income Growth % | 39.68% | 159.75% | -60.7% | 21.51% | -52.3% | 181.93% | -55.81% | 74.47% | -20.51% | 19.26% |
| EPS (Diluted) | 10.79▲ 0% | 27.71▲ 156.8% | 11.00▼ 60.3% | 13.62▲ 23.8% | 6.31▼ 53.7% | 9.04▲ 43.3% | 7.64▼ 15.5% | 13.44▲ 75.9% | 10.73▼ 20.2% | 12.99▲ 0% |
| EPS Growth % | 44.64% | 156.81% | -60.3% | 23.82% | -53.67% | 43.26% | -15.49% | 75.92% | -20.16% | -80.17% |
| EPS (Basic) | 10.91 | 28.28 | 11.25 | 13.88 | 6.35 | 9.10 | 7.73 | 13.60 | 10.90 | - |
| Diluted Shares Outstanding | 64.99M | 65.75M | 65.09M | 63.88M | 65.8M | 68.3M | 67.7M | 67.1M | 66.9M | 66.73M |
RZC Balance Sheet
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 53.1B | 60.51B | 64.53B | 76.73B | 84.66B | 92.17B | 84.9B | 97.62B | 118.67B | 152B |
| Asset Growth % | 5.39% | 13.97% | 6.64% | 18.9% | 10.33% | 8.88% | -7.89% | 14.98% | 21.56% | 90.38% |
| Total Investment Assets | 44.84B | 51.69B | 54.28B | 60.63B | 66.68B | 121.82B | 64.48B | 2.73B | 98.04B | 4M |
| Long-Term Investments | 12.67B | 13.45B | 14.14B | 52.64B | 58.46B | 60.99B | 55.52B | -57.96B | 95.86B | 392.48B |
| Short-Term Investments | 32.17B | 38.24B | 40.13B | 8.62B | 8.37B | 60.84B | 7.82B | 60.69B | 2.18B | 12.95B |
| Total Current Assets | 34.06B | 1.3B | 42.78B | 0 | 0 | 66.36B | 0 | 2.97B | 11.04B | 0 |
| Cash & Equivalents | 1.2B | 1.3B | 1.89B | 1.45B | 3.41B | 2.95B | 2.93B | 2.97B | 3.33B | 4.63B |
| Receivables | 683.97M | 782.03M | 758M | 904M | 983M | 2.58B | 2.67B | 5.45B | 5.53B | 22.09B |
| Other Current Assets | 0 | 0 | 0 | -10.97B | -12.76B | 0 | -13.42B | -66.14B | 0 | -23.33B |
| Goodwill & Intangibles | 71.3M | 59.3M | 85.2M | 230M | 213M | 193M | 164M | 154M | 133M | 5.78B |
| Goodwill | 7M | 7M | 7M | 7M | 7M | 7M | 0 | 0 | 0 | 0 |
| Intangible Assets | 64.3M | 52.3M | 78.2M | 223M | 206M | 186M | 164M | 154M | 133M | 0 |
| PP&E (Net) | 0 | 0 | 0 | 244M | 260M | 284M | 270M | 279M | 325M | 0 |
| Other Assets | 39.15B | 45.7B | 48.42B | -53.11B | -58.93B | -14M | -55.95B | 140.63B | 11.32B | -103.76B |
| Total Liabilities | 46B | 50.95B | 56.09B | 65.13B | 70.3B | 79.16B | 77.73B | 88.45B | 107.77B | 138.94B |
| Total Debt | 3.93B | 3.57B | 3.47B | 3.98B | 4.36B | 3.85B | 4.36B | 4.43B | 5.04B | 5.73B |
| Net Debt | 2.73B | 2.27B | 1.58B | 2.53B | 953M | 899M | 1.43B | 1.46B | 1.72B | 1.11B |
| Long-Term Debt | 3.93B | 3.57B | 3.47B | 3.58B | 3.96B | 3.85B | 3.96B | 4.43B | 5.04B | 5.73B |
| Short-Term Debt | 0 | 0 | 0 | 400M | 400M | 0 | 400M | 0 | 0 | 0 |
| Total Current Liabilities | 688.93M | 488.74M | 487M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | 388.99M | 488.74M | 487M | 557M | 598M | 613M | 756M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 213M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 299.94M | -488.74M | -487M | -957M | -998M | -826M | -1.89B | -4.48B | -5.02B | -5.28B |
| Deferred Taxes | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 9.49B |
| Other Liabilities | 38.62B | 45.17B | 52.62B | -6.29B | -7.22B | 72.43B | -5.34B | 82.16B | 100.53B | -8.32B |
| Total Equity | 7.09B▲ 0% | 9.57B▲ 34.9% | 8.45B▼ 11.7% | 11.6B▲ 37.3% | 14.35B▲ 23.7% | 13.01B▼ 9.3% | 7.17B▼ 44.9% | 9.17B▲ 27.9% | 10.91B▲ 18.9% | 13.07B▲ 0% |
| Equity Growth % | 15.61% | 34.91% | -11.69% | 37.28% | 23.71% | -9.32% | -44.9% | 27.89% | 18.92% | 79.25% |
| Shareholders Equity | 7.09B | 9.57B | 8.45B | 11.6B | 14.35B | 13.01B | 7.08B | 9.08B | 10.82B | 12.98B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 90M | 90M | 90M | 90M |
| Retained Earnings | 5.2B | 6.74B | 7.28B | 7.95B | 8.15B | 8.56B | 8.17B | 8.8B | 9.26B | 9.76B |
| Common Stock | 791K | 791K | 791K | 1M | 1M | 1M | 1M | 1M | 1M | 1M |
| Accumulated OCI | 1.14B | 2.06B | 636.76M | 3.14B | 5.36B | 3.64B | -1.87B | -369M | 849M | 2.55B |
| Return on Equity (ROE) | 10.61% | 21.87% | 7.95% | 8.68% | 3.2% | 8.55% | 5.12% | 11.04% | 7.14% | 6.63% |
| Return on Assets (ROA) | 1.36% | 3.21% | 1.15% | 1.23% | 0.51% | 1.32% | 0.58% | 0.99% | 0.66% | 0.57% |
| Equity / Assets | 13.36% | 15.81% | 13.09% | 15.12% | 16.95% | 14.12% | 8.45% | 9.39% | 9.19% | 8.6% |
| Debt / Equity | 0.55x | 0.37x | 0.41x | 0.34x | 0.30x | 0.30x | 0.61x | 0.48x | 0.46x | 0.46x |
| Book Value per Share | 109.14 | 145.54 | 129.82 | 181.60 | 218.12 | 190.54 | 105.92 | 136.68 | 163.02 | 195.83 |
| Tangible BV per Share | 108.05 | 144.64 | 128.51 | 178.00 | 214.88 | 187.72 | 103.50 | 134.38 | 161.03 | 195.83 |
RZC Cash Flow Statement
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 1.47B | 1.98B | 1.58B | 2.31B | 3.32B | 4.18B | 1.34B | 4.04B | 9.37B | 9.37B |
| Operating CF Growth % | -29.82% | 35.24% | -20.24% | 45.91% | 44% | 25.89% | -67.89% | 201.12% | 131.7% | -67% |
| Operating CF / Revenue % | 12.72% | 15.84% | 12.28% | 16.25% | 22.78% | 26.04% | 8.46% | 21.99% | 42.51% | 42.07% |
| Net Income | 701.44M | 1.82B | 715.84M | 870M | 415M | 617M | 517M | 902M | 717M | 867M |
| Depreciation & Amortization | 26.85M | 53M | 45.13M | 49M | 3M | -11M | 38M | 41M | 46M | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 39M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 76.51M | 0 | -16M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 136.49M | -249.14M | 5.38M | -31M | -62M | -731M | 346M | -116M | 343M | -3.7B |
| Working Capital Changes | 600.93M | 356.27M | 738.26M | 1.38B | 2.98B | 4.31B | 442M | 3.22B | 8.26B | 8.25B |
| Cash from Investing | -2.83B | -1.61B | -636.55M | -2.64B | -2.68B | -4.63B | -5.69B | -4.07B | -12.54B | -12.99B |
| Capital Expenditures | -44.64M | -44.21M | -28.89M | -34M | -28M | -19M | -25M | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | -31.44M | 4M | -173M | -287M | 17M | -77M | -320M | -3M |
| Purchase of Investments | -8.1B | -8.94B | -10.1B | -16.28B | -10.26B | -18.28B | -17.07B | -13.25B | -41.69B | -39.75B |
| Sale/Maturity of Investments | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 4M |
| Other Investing | -641.52M | -657.07M | -615.69M | -442M | 115M | 129M | -60M | 711M | -1.03B | -2.77B |
| Cash from Financing | 1.06B | -324.62M | -321.97M | -121M | 1.25B | 20M | 4.44B | 78M | 3.66B | 7.61B |
| Dividends Paid | -100.37M | -117.29M | -140.11M | -163M | -182M | -194M | -205M | -219M | -229M | -237M |
| Share Repurchases | -122.92M | -44M | -299.68M | -101M | -163M | -99M | -81M | -227M | -27M | -39M |
| Stock Issued | 0 | 0 | 0 | 0 | 481M | 0 | 0 | 0 | 0 | 0 |
| Debt Issuance (Net) | 1000K | -1000K | -1000K | 1000K | 1000K | -1000K | 1000K | 1000K | 1000K | -1000K |
| Other Financing | 545.74M | 207.67M | 217.14M | 38M | 737M | 430M | 4.62B | 62M | 3.31B | 7.22B |
| Net Change in Cash | -324.56M▲ 0% | 102.81M▲ 131.7% | 586.21M▲ 470.2% | -441M▼ 175.2% | 1.96B▲ 544.2% | -460M▼ 123.5% | -21M▲ 95.4% | 43M▲ 304.8% | 356M▲ 727.9% | -570M▲ 0% |
| Exchange Rate Effect | -1000K | 1000K | -1000K | 1000K | 1000K | -1000K | -1000K | -1000K | -1000K | 0 |
| Cash at Beginning | 1.53B | 1.2B | 1.3B | 1.89B | 1.45B | 3.41B | 2.95B | 2.93B | 2.97B | 5.42B |
| Cash at End | 1.2B | 1.3B | 1.89B | 1.45B | 3.41B | 2.95B | 2.93B | 2.97B | 3.33B | 4.63B |
| Free Cash Flow | 1.42B▲ 0% | 1.94B▲ 36.4% | 1.55B▼ 19.9% | 2.27B▲ 46.4% | 3.29B▲ 44.9% | 4.16B▲ 26.4% | 1.34B▼ 67.7% | 4.04B▲ 201.1% | 9.37B▲ 131.7% | 4.84B▲ 0% |
| FCF Growth % | -31.18% | 36.38% | -19.91% | 46.43% | 44.92% | 26.38% | -67.74% | 201.12% | 131.7% | -46.33% |
| FCF Margin % | 12.33% | 15.48% | 12.06% | 16.01% | 22.59% | 25.92% | 8.46% | 21.99% | 42.51% | 21.73% |
| FCF per Share | 21.87 | 29.48 | 23.85 | 35.58 | 50.06 | 60.95 | 19.84 | 60.27 | 140.06 | 140.06 |
RZC Key Ratios
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Combined Ratio | 90.94% | 90.87% | 93.43% | 92.03% | 96.21% | 91.38% | 95.48% | 93.69% | 95.55% | 94.36% |
| Medical Cost Ratio | 83.92% | 83.8% | 85.95% | 85.2% | 89.41% | 88.46% | 90.11% | 87.33% | 88.71% | 86.92% |
| Return on Equity (ROE) | 10.61% | 21.87% | 7.95% | 8.68% | 3.2% | 8.55% | 5.12% | 11.04% | 7.14% | 6.63% |
| Return on Assets (ROA) | 1.36% | 3.21% | 1.15% | 1.23% | 0.51% | 1.32% | 0.58% | 0.99% | 0.66% | 0.57% |
| Equity / Assets | 13.36% | 15.81% | 13.09% | 15.12% | 16.95% | 14.12% | 8.45% | 9.39% | 9.19% | 8.6% |
| Book Value / Share | 109.14 | 145.54 | 129.82 | 181.6 | 218.12 | 190.54 | 105.92 | 136.68 | 163.02 | 195.83 |
| Debt / Equity | 0.55x | 0.37x | 0.41x | 0.34x | 0.30x | 0.30x | 0.61x | 0.48x | 0.46x | 0.46x |
| Revenue Growth | 10.59% | 8.63% | 2.88% | 10.27% | 2.71% | 10.13% | -1.13% | 15.82% | 19.85% | 2.28% |
RZC SEC Filings & Documents
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) SEC filings — annual & quarterly reports (10-K, 10-Q)
RZC Frequently Asked Questions
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) grew revenue by 19.9% over the past year. This is strong growth.
Yes, 7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) is profitable, generating $867.0M in net income for fiscal year 2024 (3.3% net margin).
Dividend & Returns
Yes, 7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) pays a dividend with a yield of 13.48%. This makes it attractive for income-focused investors.
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) has a return on equity (ROE) of 7.1%. This is below average, suggesting room for improvement.
Industry Metrics
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) has a combined ratio of 95.6%. A ratio below 100% indicates underwriting profitability.
Explore More RZC
7.125% Fixed-Rate Reset Subordinated Debentures due 2052 (RZC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates